Tyrosine kinase inhibitor cabozantinib impacts dendritic and natural killer cells immune response in C38 syngeneic tumor model

Eur J Immunol. 2023 Jun;53(6):e2250186. doi: 10.1002/eji.202250186. Epub 2023 Apr 25.

Authors

Jordane Divoux¹, Sylvie Rolland¹, Raphael Delille¹, Clément Levin², Vincent Martin², Pamela Young¹, Florence Meyer-Losic¹, Stephan Klinz³

Affiliations

¹ Translational Biomarkers and Pharmacology, IPSEN, Les Ulis, France.
² Investigative Pathology and Safety Biomarkers, IPSEN, Les Ulis, France.
³ Early Development & Translational Sciences, IPSEN, Cambridge, MA, USA.

PMID: 37056029
DOI: 10.1002/eji.202250186

No abstract available

Keywords: C38 syngeneic tumor model; Cabozantinib; Dendritic cells; Natural killer; Tyrosine kinase inhibitor.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Humans
Immunity
Killer Cells, Natural
Neoplasms* / drug therapy
Protein Kinase Inhibitors / pharmacology
Protein Kinase Inhibitors / therapeutic use
Tyrosine Kinase Inhibitors*

Substances

cabozantinib
Tyrosine Kinase Inhibitors
Protein Kinase Inhibitors